(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Moran Sean F.			2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						5. F	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
C/O CORBU INC, 100 RIV		(First) MACEUTICALS BE DRIVE		3. Date of Earliest Transaction (Month/Day/Year) , 01/04/2018					X	X Officer (give title below) Other (specify below) Chief Financial Officer						
(Street)			4	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
NORWOOD	, MA 0206											onn med by M	ore man One Ke	porting reison		
(City)		(State)	(Zip)			Table	I - N	on-Dei	rivativ	e Securities	Acquired	, Disposed o	f, or Benefi	cially Owned		
1.Title of Security (Instr. 3)			Date (Month/Day/Year)	2A. Deemed Execution Date) any (Month/Day/Ye	Date,	if Cod (Inst	3. Transacti Code (Instr. 8)		(A) or Disposed of (Instr. 3, 4 and 5)		f (D) Owned Followin Transaction(s)			O Fo	wnership of orm: Be	Beneficial
					ay/Yea		ode	v	(A) or Amount (D) Price			or (I)	Indirect (In	wnership nstr. 4)		
Reminder: Repo	ort on a sepa	rate line for each cl	Table II - l	Derivative	Secur	ties Ac	quir	Perso in this a curr	ons wi s form ently		quired to control i	respond (number.		on contained form display		74 (9-02)
Derivative Security (Instr. 3)	Conversion	(Month/Day/Year)	3A. Deemed Execution Date, if	4. 5. N , if Transaction Der Code Sec ear) (Instr. 8) Acc or I		Numberivative curities equired Dispos (D)	Number of rivative curities quired (A) Disposed (D) str. 3, 4,		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercis		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option(right to buy)	\$ 8.35	01/04/2018		A	17	75,000		<u>(1</u>	7	01/04/2028	Commo	n 175,000	\$ 0	175,000	D	
Renartii	ng Ow	ners														

Reporting Owners

Describes Occurs Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Moran Sean F. C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062			Chief Financial Officer				

Signatures

/s/ Sean Moran	01/05/2018
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.